Endocrinology

ATTD 2026: Registry data from US primary care practices showed Dexcom G7 use lowered HbA1c by 0.7% over 1 year in adults with noninsulin-treated type 2 diabetes.

The FDA issued 30 warning letters to telehealth firms for false or misleading claims about compounded GLP-1 products, citing illegal marketing practices.

GLP‑1 therapy reduces asthma flare-ups in overweight non‑diabetics, suggesting a promising add-on for obesity-related asthma care.

FDA approves DESMODA, a ready-to-use desmopressin acetate oral solution, enabling precise titration for central diabetes insipidus with key hyponatremia warnings.

Obesity medicine specialist Monu Khanna, MD, discusses the critical role of primary care in obesity-related risk reduction through lifestyle, behavior, and emerging therapies.

The FDA updates Afrezza's prescribing information, enhancing dosing guidance for adults switching from injected insulin to improve glycemic control.

FDA requests removal of suicidal ideation warnings from GLP-1 receptor agonist labeling after a comprehensive review found no increased risk.

Weight-loss interventions significantly enhance psoriasis severity and quality of life, emphasizing their role in effective psoriasis management strategies.

A nephrology expert reviews how workflow constraints and care delivery pressures affect adherence to guideline-recommended responses to elevated urine albumin-to-creatinine ratio.

A nephrology expert discusses survey findings that reveal gaps between UACR testing and action in cardiovascular risk assessment for type 2 diabetes.

FDA prioritizes review of Tzield for young children with stage 2 type 1 diabetes, potentially delaying disease onset and improving patient outcomes.

The FDA approved once-daily oral semaglutide 25 mg for chronic weight management and long-term weight maintenance in adults with obesity or overweight, based on data from the OASIS clinical trial program.

Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.

CGM users experienced fewer ED and inpatient days and better glycemic outcomes, but most eligible adults in this large cohort did not use the technology.

Ob/gyn Dorr outlines how short clinical visits and symptom overlap cause many women to receive an antidepressant Rx instead of perimenopause care.

The 2026 annual updates to the Standards of Care in Diabetes include wider CGM use, guidance on dosing of antiobesity drugs, and glycemic management during cancer therapy.

Insulet enhances the Omnipod® 5 system with new glucose targets and algorithms, improving insulin delivery for diabetes management.

Semaglutide did not slow AD progression in phase 3 evoke trials. UK and US experts express disappointment but laud value of outcomes to continuing research.

Biomarker trajectories over 5 years in study participants with AD show steeper rises in pTau217, NfL, and amyloid burden among those with obesity, highlighting risk factor relevance.

The landmark global policy recognizes obesity as chronic disease requiring lifelong care, warns of inequitable access and proposes 3-pillar strategy targeting prevention, screening, treatment.

Dorr says symptoms can begin 10 years before cylces cease and explains why the hormonal feast and famine of perimenopause can go unrecognized.

GLORY-2 participants showed continuous weight loss through 60 weeks with no plateau; mazdutide also improved multiple cardiometabolic markers.

FDA approves Dexcom Smart Basal, a groundbreaking CGM-integrated insulin dosing optimizer, enhancing diabetes management for adults with Type 2 diabetes.

A new study reveals that the Preventive Health Inventory enhances diabetes and hypertension management among veterans without increasing hospitalizations.

In the phase 2 clinical trial, tradipitant, an oral neurokinin-1 receptor antagonist, was dosed twice daily among adults with obesity and treated with semaglutide.